Demographics (2)
- AGE_DX - Age at diagnosis (phv00395305.v1.p1)
- GENDER - Gender of the patient (phv00395307.v1.p1)
Disease Events (6)
- AFFECTION_STATUS - Case control status of the subject for (phv00395298.v1.p1)
- AXILLARY_NODES_EXAMINED - Number of axillary lymph nodes examined (phv00395345.v1.p1)
- AXILLARY_NODES_POSITIVE - Number of axillary lymph nodes containing cancer (phv00395344.v1.p1)
- TUMOR_CELLULARITY - Percentage of tumor cells present in the sample (phv00395337.v1.p1)
- TUMOR_GRADE - Definition of histologic tumor grade of sample (phv00395348.v1.p1)
- TUMOR_GRADE_SCORE - Tumor grade score given to the sample (phv00395349.v1.p1)
Race and Ethnicity (1)
- ETHNICITY - Ethnicity of the patient (phv00395306.v1.p1)
Other (54)
- ANALYTE_TYPE - Analyte type used for experiment (phv00395334.v1.p1)
- AXILLARY_NODES_FIXED - Axillary lymph node is fixed to other structures (phv00395346.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00395332.v1.p1)
- CN/PLOIDY17p_RATIO - Ratio of HER2 copy number by 17p ploidy (phv00395326.v1.p1)
- CN/PLOIDY17q_RATIO - Ratio of HER2 copy number by 17q ploidy (phv00395327.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00395295.v1.p1)
- DISTANT_METASTASIS_M - Definition of distant metastasis (M) (phv00395343.v1.p1)
- ER_ALLRED_SCORE - Allred score assigned by pathologist for ER status (phv00395309.v1.p1)
- ER_INTENSITY - Intensity score of ER positive staining by IHC (phv00395310.v1.p1)
- ER_PERCENT_SCORE - Percentage of cells for nuclear positivity for ER by IHC (phv00395311.v1.p1)
- ER_STATUS - Status of Estrogen Receptor (ER) expression in the tumor as measured by Immunohistochemistry (IHC) (phv00395308.v1.p1)
- FOCAL - Focal amplification of HER2 (phv00395322.v1.p1)
- HER2_AMPLIFIED - Status of HER2 copy number amplification as measured using PureCN algorithm and assessed by clinical oncologist (phv00395321.v1.p1)
- HER2_COPY_NUMBER - HER2 copy number adjusted for purity and ploidy using PureCN algorithm (phv00395323.v1.p1)
- HER2_IHC_SCORE - Score given for degree of HER2 amplification by IHC (phv00395318.v1.p1)
- HER2_INTENSITY - Intensity score of HER2 positive staining by IHC (phv00395319.v1.p1)
- HER2_PERCENT_SCORE - Percentage of cells with uniform intense complete membrane staining for HER2 by IHC (phv00395320.v1.p1)
- HER2_STATUS - Overall result of Human Epidermal Growth Factor Receptor-2 (HER2) status as measured by IHC and copy number (phv00395316.v1.p1)
- HER2_STATUS_IHC - Status of HER2 copy number amplification as measured by IHC (phv00395317.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00395338.v1.p1)
- IS_TUMOR - Tumor status (phv00395336.v1.p1)
- NODAL_INVOLVEMENT_N - Definition of regional lymph node (N) (phv00395342.v1.p1)
- PAM50_SUBTYPE - Intrinsic molecular subtyping (PAM50 subtype) of tumor using the genefu algorithm (phv00395328.v1.p1)
- PLOIDY - Ploity of tumor as measured by ASCAT algorithm (phv00395330.v1.p1)
- PLOIDY_17p - Ploidy of chromosome 17p arm as measured using PureCN algorithm (phv00395324.v1.p1)
- PLOIDY_17q - Ploidy of chromosome 17q arm as measured using PureCN algorithm (phv00395325.v1.p1)
- PR_ALLRED_SCORE - Allred score assigned by pathologist for PR expression (phv00395313.v1.p1)
- PR_INTENSITY - Intensity score of PR positive staining by IHC (phv00395314.v1.p1)
- PR_PERCENT_SCORE - Percentage of cells with nuclear positivity for PR by IHC (phv00395315.v1.p1)
- PR_STATUS - Status of Progesterone Receptor (PR) expression in the tumor as measured by IHC (phv00395312.v1.p1)
- PRESERVATION_METHOD - Chemical preservative used to preserve samples (phv00395335.v1.p1)
- PRIMARY_METASTATIC_TUMOR - Primary tumor or metastasis (phv00395339.v1.p1)
- PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00395340.v1.p1)
- PRIMARY_TUMOR_T - Definition of primary tumor (T) (phv00395341.v1.p1)
- PURITY - Purity of tumor as measured by ASCAT algorithm (phv00395329.v1.p1)
- RNAseq_BATCH - Batch number of RNA sequencing (phv00395355.v1.p1)
- SAMPLE_ID - De-identified sample ID (phv00395331.v1.p1)
- SAMPLE_ID - Sample ID (phv00395300.v1.p1)
- SAMPLE_SOURCE - Source repository where samples originate (phv00395301.v1.p1)
- SAMPLE_TYPE - Sample type collected from patient (phv00395333.v1.p1)
- SAMPLE_USE - Sample Use (phv00395303.v1.p1)
- SEQUENCING_CENTER - Name of the center that conducted sequencing (phv00395351.v1.p1)
- SEQUENCING_LIBRARY_REAGENT - Name of the library reagent used for sequencing (phv00395353.v1.p1)
- SEQUENCING_PLATFORM - Name of Illumina sequencing platform used (phv00395352.v1.p1)
- SOURCE_SAMPLE_ID - Sample ID used in the Source Repository (phv00395302.v1.p1)
- SOURCE_SUBJECT_ID - Subject ID used in the Source Repository (phv00395297.v1.p1)
- SUBJECT_ID - De-identified subject ID (phv00395304.v1.p1)
- SUBJECT_ID - Subject ID (phv00395294.v1.p1)
- SUBJECT_ID - Subject ID (phv00395299.v1.p1)
- SUBJECT_SOURCE - Source repository where subjects originate (phv00395296.v1.p1)
- TNM_STAGE - Pathological tumor staging of sample (phv00395347.v1.p1)
- TUMOR_TREATMENT - Type of tumor treatment for sample (phv00395350.v1.p1)
- WES_BATCH - Batch number of whole-exome sequencing (phv00395354.v1.p1)
- WGS_BATCH - Batch number of whole-genome sequencing (phv00395356.v1.p1)